Organoids Model Transcriptional Hallmarks of Oncogenic KRAS Activation in Lung Epithelial Progenitor Cells

类器官模型模拟肺上皮祖细胞中致癌KRAS激活的转录特征

阅读:4
作者:Antonella F M Dost ,Aaron L Moye ,Marall Vedaie ,Linh M Tran ,Eileen Fung ,Dar Heinze ,Carlos Villacorta-Martin ,Jessie Huang ,Ryan Hekman ,Julian H Kwan ,Benjamin C Blum ,Sharon M Louie ,Samuel P Rowbotham ,Julio Sainz de Aja ,Mary E Piper ,Preetida J Bhetariya ,Roderick T Bronson ,Andrew Emili ,Gustavo Mostoslavsky ,Gregory A Fishbein ,William D Wallace ,Kostyantyn Krysan ,Steven M Dubinett ,Jane Yanagawa ,Darrell N Kotton ,Carla F Kim

Abstract

Mutant KRAS is a common driver in epithelial cancers. Nevertheless, molecular changes occurring early after activation of oncogenic KRAS in epithelial cells remain poorly understood. We compared transcriptional changes at single-cell resolution after KRAS activation in four sample sets. In addition to patient samples and genetically engineered mouse models, we developed organoid systems from primary mouse and human induced pluripotent stem cell-derived lung epithelial cells to model early-stage lung adenocarcinoma. In all four settings, alveolar epithelial progenitor (AT2) cells expressing oncogenic KRAS had reduced expression of mature lineage identity genes. These findings demonstrate the utility of our in vitro organoid approaches for uncovering the early consequences of oncogenic KRAS expression. This resource provides an extensive collection of datasets and describes organoid tools to study the transcriptional and proteomic changes that distinguish normal epithelial progenitor cells from early-stage lung cancer, facilitating the search for targets for KRAS-driven tumors.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。